Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

ProSALUTE: Community Program for Cardiovascular Health (ProSALUTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03129165
Recruitment Status : Unknown
Verified April 2017 by José Pablo Werba, Centro Cardiologico Monzino.
Recruitment status was:  Enrolling by invitation
First Posted : April 26, 2017
Last Update Posted : April 26, 2017
Sponsor:
Information provided by (Responsible Party):
José Pablo Werba, Centro Cardiologico Monzino

Brief Summary:
The purpose of this study is to determine the efficacy and cost/effectiveness (change in CV risk factors and lifestyle vs costs) of ProSALUTE as a new organizational model of primary CV prevention.

Condition or disease Intervention/treatment Phase
Primary Prevention Other: Screening and prevention of CVD Not Applicable

Detailed Description:

Primary Cardiovascular (CV) prevention programs in the healthcare place and community-based interventions have a variable impact on health at the population level. The largest benefit may be obtained by addressing high-risk, disadvantaged and traditionally hard-to-reach groups.

Effective actions include health promotion, timely screening of modifiable risk factors, application of evidence-based targets and interventions, broad access to heart-friendly environments/facilities and dissemination of favorable social norms. Thus, community prevention is a multifaceted task that requires multidisciplinary collaboration. A suitable program should be tailored to the specific social context and make the most of local resources to improve access, adherence and continuity, as well as sustainability.

ProSALUTE is a new model of primary CV prevention for the prevalently low-income and multiethnic community of Ponte Lambro (n=3600 adults), the neighborhood where the coordinating hospital (Centro Cardiologico Monzino, Milan, Italy) is located.

Under the coordination of a Case Manager (a Nursing Researcher) the citizens are involved in a prevention program, which is personalized (content and intensity) according to the individual global risk and specific risk factors. The citizens follow an individualized schedule of short-term specialist care. Besides, the participants are "gently nudged" to make use of local resources that may contribute to sustain a healthy life-style (e.g. parks, gyms, social services, etc). Moreover, public preventive events for the community are devised (e.g. healthy-cooking course, walking groups, etc) through a collaborative network with representatives of the neighborhood.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: ProSALUTE: a New Community Program for Cardiovascular Health
Actual Study Start Date : May 11, 2015
Estimated Primary Completion Date : May 11, 2018
Estimated Study Completion Date : May 11, 2018

Arm Intervention/treatment
Experimental: Screening and prevention of CVD Other: Screening and prevention of CVD

Drug: Pharmacological control of risk factors in agreement with primary physicians.

Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.

Social: Social worker care.





Primary Outcome Measures :
  1. Primary adherence at baseline screening [ Time Frame: Baseline ]
    Primary adherence evaluated as the ratio between the number of subjects enrolled and the number of subjects actively contacted through personal postal mail


Secondary Outcome Measures :
  1. Influence of education level on primary adherence [ Time Frame: Baseline ]
    Assessed as rate of primary adherence according to educational level (years of schooling <8, 8-12 or >12)

  2. Influence of working category on primary adherence [ Time Frame: Baseline ]
    Assessed as rate of primary adherence according to working category (manual worker, service worker, office worker, unemployed, retired)

  3. Influence of immigrant or native status on primary adherence [ Time Frame: Baseline ]
    Assessed as rate of primary adherence according to immigrant (from any country) or native status

  4. Awareness of own cardiovascular risk factors [ Time Frame: Baseline ]
    Awareness assessed as prevalence of knowledge (answer: known value or not known) of levels of the following personal cardiovascular risk factors: total cholesterol, triglycerides, glycaemia, systolic and diastolic blood pressure

  5. Accuracy of the perception of own cardiovascular risk [ Time Frame: Baseline ]
    Accuracy assessed as concordance (using Cohen's kappa test) between risk perception (evaluated through a 5 point Likert scale questionnaire: from very low to very high) and estimated cardiovascular risk (evaluated through the Framingham Risk Score)

  6. Prevalence of positive screening for anxiety [ Time Frame: Baseline ]
    Anxiety assessed using General Anxiety Disorder 2 (GAD-2) test and defined as positive with a score ≥3

  7. Prevalence of positive screening for depression [ Time Frame: Baseline ]
    Depressive mood assessed using Patient Health Questionnaire 2 (PHQ-2) test and defined as positive with a score ≥3

  8. Extent of adherence to the Mediterranean Diet (MD) [ Time Frame: Baseline ]
    Extent of adherence to MD assessed using the PREDIMED questionnaire and score, using three categories (0-7 low adherence; 8-9 medium adherence, ≥10 high adherence)

  9. Prevalence of physically active subjects [ Time Frame: Baseline ]
    Physical activity (PA) assessed using the PASSI questionnaire and physically active subjects defined according to the WHO 2010 Guidelines

  10. Human resources utilization [ Time Frame: Baseline ]
    Percent of enrolled subjects allocated to medical visit, interview with nutritionist, motivational interview to promote physical activity, smoking-cessation program, interview with psychologist

  11. Persistence in the program at 6th months [ Time Frame: 6 months ]
    Persistence assessed as the ratio between subjects followed at 6 months and subjects enrolled

  12. Changes in adherence to MD at 6 months [ Time Frame: 6 months ]
    Assessed as the net improvement in category of adherence to MD (number of those who increased minus number of those who decreased)

  13. Changes in PA at 6 months [ Time Frame: 6 months ]
    Assessed as the net improvement in category of PA level (number of sedentary subjects shifted to active or moderate minus number of active or moderate shifted to sedentary)

  14. Changes in declared cigarette consumption [ Time Frame: 6 months ]
    Assessed as the net improvement in extent of cigarette consumption (number of smokers who reduced the number of cigarettes/day minus number of smokers who increased the number of cigarettes/day)

  15. Changes in objective measures of cigarette smoke exposure [ Time Frame: 6 months ]
    Assessed as the net improvement in exhaled Carbon Monoxide (CO) (number of smokers who reduced ≥10% exhaled CO ppm minus number of smokers who increased ≥10% exhaled CO ppm)

  16. Change in positive screening for anxiety [ Time Frame: 6 months ]
    Assessed as the net improvement in screening for anxiety (number of positive who became negative minus number of negative who became positive)

  17. Change in positive screening for depression [ Time Frame: 6 months ]
    Assessed as the net improvement in screening for depression (number of positive who became negative minus number of negative who became positive)

  18. Global change in traditional risk factors at 6th months [ Time Frame: 6 months ]
    Assessed as the number of subjects who improved by ≥10% at least one traditional CV risk factor measure without worsening by ≥10% any other CV risk factor measure. The CV risk factors considered are: glycaemia >126 mg/dl, LDL-C >115 mg/dl, systolic blood pressure >140 mmHg and BMI >28

  19. Global change in estimated risk at 6th months [ Time Frame: 6 months ]
    Assessed as net improvement in Framingham Risk Score (number of subjects who reduced the score minus number of subjects who increased the score)

  20. Persistence in the program at 12th months [ Time Frame: 12 months ]
    Persistence assessed as the ratio between subjects followed at 12 months and subjects enrolled

  21. Global change in traditional risk factors at 12th months [ Time Frame: 12 months ]
    Assessed as the number of subjects who improved by ≥10% at least one traditional CV risk factor measure without worsening by ≥10% any other CV risk factor measure. The CV risk factors considered are: glycaemia >126 mg/dl, LDL-C >115 mg/dl, systolic blood pressure >140 mmHg and BMI >28

  22. Global change in estimated risk at 12th months [ Time Frame: 12 months ]
    Assessed as net improvement in Framingham Risk Score (number of subjects who reduced the score minus number of subjects who increased the score)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Live in Milan at neighborhood of Ponte Lambro

Exclusion Criteria:

  • Patients with known atherosclerotic disease (secondary prevention)
  • Severe diseases or disabilities that hinder the participation in the program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03129165


Locations
Layout table for location information
Italy
Centro Cardiologico Monzino
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Investigators
Layout table for investigator information
Principal Investigator: José Pablo P Werba, MD Centro Cardiologico Monzino

Additional Information:
Layout table for additonal information
Responsible Party: José Pablo Werba, Head of Unit of Atherosclerosis Prevention, Principal Investigator, Specialist in Internal Medicine, Centro Cardiologico Monzino
ClinicalTrials.gov Identifier: NCT03129165     History of Changes
Other Study ID Numbers: R212/15 - CCM 226
First Posted: April 26, 2017    Key Record Dates
Last Update Posted: April 26, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by José Pablo Werba, Centro Cardiologico Monzino:
Cardiovascular diseases
Public Health
Hypertension
Smoking
Hypercholesterolemia
Food Habits
Exercise
Anxiety
Depression
Obesity
Diabetes